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Acute and chronic lung injury represents a major and growing global burden of disease. For many of these lung diseases, the
damage is irreparable, exhausting the host’s ability to regenerate new lung, and current therapies are simply supportive rather than
restorative. Cell-based therapies oﬀer the promise of tissue regeneration for many organs. In this paper, we examine the potential
application of amnion epithelial cells, derived from the term placenta, to lung regeneration. We discuss their unique properties of
plasticity and immunomodulation, reviewing the experimental evidence that amnion epithelial cells can prevent and repair lung
injury, oﬀering the potential to be applied to both neonatal, childhood, and adult lung disease. It is amazing to suggest that the
placenta may oﬀer renewed life after birth as well as securing new life before.
1.Introduction
Chronic lung diseases, in both children and adults, are
leading causes of morbidity and mortality worldwide, esti-
mated to account for about 10% of global mortality [1]. It
has been estimated by the World Health Organization that,
by 2030, chronic lung disease, mainly caused by tobacco
smoking, occupational irritant exposure and pollution, will
become the third most common cause of death worldwide
[1]. However, mortality is just the tip of the iceberg. A
recent economic analysis of the burden of chronic lung
disease in Australia revealed that almost 1 in 5 adults aged
40 or older have chronic obstructive pulmonary disease
(COPD)tosomedegree,withhalfoftheseindividualshaving
advanced disease [2]. The estimated ﬁnancial cost of COPD
in Australia in 2008 was nearly $9 billion. Further, chronic
lung disease does not only aﬀect adults. About 1 in 80
children aged under 10 suﬀer morbidity from COPD. In
particular, over recent decades advances in perinatal care
have greatly improved the survival chances of very preterm
babies,principallythroughthereductionofacuterespiratory
distress syndrome (RDS) by antenatal corticosteroids and
postnatal surfactant therapies [3, 4]. However, almost a
third of these survivors develop chronic neonatal lung
disease, so called bronchopulmonary dysplasia (BPD), a
disease with the consequent long-term burdens of childhood
respiratory dysfunction and neurodevelopmental delay [5].
Unfortunately, both neonatal BPD and adult COPD have
an important feature in common. Neither have an eﬀective
treatment.
Accordingly, together, these childhood and adult chronic
lung conditions represent a signiﬁcant and growing burden
of disease for which there is no targeted intervention that
might restore lung function and thereby reduce morbidity
and mortality. However, while the causes of childhood and
adult COPD diﬀer, the fundamental lung injury is similar—
chronic inﬂammation, ﬁbrosis, and scarring [6–8]—and
the clinical end result—loss of functional lung tissue—
is identical. As such these chronic lung diseases may be
amenable to regeneration, which may be aﬀorded by cell-
based therapies. In this paper we review the recent advances
in the application of placenta-derived cells as a potential
therapy for human lung disease. Speciﬁcally, we will review
the unique properties of amnion, the eﬀect of amnion cells
on diﬀerent models of lung injury and explore the likely
mechanisms of action of amnion cells in lung repair with a
view to human clinical trials.2 Stem Cells International
2. UniqueTherapeutic Properties of Amnion
Epithelial Cells
At the ﬁrst international workshop on placenta-derived stem
cells, convened in Brescia, Italy in 2007, two key properties
of placental cells that make them attractive for regenerative
medicinewerehighlighted:plasticityandimmunomodulation
[9]. Human amnion epithelial cells (hAECs) are a subset
of placental-derived stem cells that display both of these
key features and, perhaps, possess advantages over the other
populations of stem cell-like cells in the placental tissues.
First, the amnion itself is derived from the embryonic
epiblast prior to gastrulation. This is important because
cells derived from the epiblast prior to gastrulation are
thoughttoretainmultipotentmemory orplasticity,reﬂecting
the capability of the epiblast itself to diﬀerentiate into
the ectoderm, endoderm, and mesoderm of the deﬁnitive
embryo. Thus, at least theoretically, amnion cells should
be capable of diﬀerentiation down each primary lineage.
Over the past 6 years or so we, and others, have care-
fully characterized human amnion epithelial cells (hAECs),
deﬁning cell types and asking whether they share any
transcriptional factors with embryonic stem cells that might
confer pluripotentiality. First, cells isolated from amniotic
membranes by simple digest are essentially exclusively
epithelial cells [10]. These human amnion epithelial cells
(hAECs) do not express mesenchymal or haematopoietic cell
markers and diﬀer from cells derived from amniotic ﬂuid
in early to midpregnancy [10–12]. This distinction between
amniotic membrane-derived amnion epithelial cells, and
amniotic ﬂuid stem cells is that the former are a pure
population of epithelial cells while the latter are a mixed
cell population of mesenchymal, stromal, and epithelial cells.
This diﬀerence is important to keep in mind when assessing
possible therapeutic and regenerative medicine applications
for each of these cell populations, as will be discussed later.
However, while hAECs are all epithelial cells they are still a
heterogeneous population of epithelial cells with diverse cell
marker expression. Importantly, these cell lineage markers
include early “stem cell” markers such as the POU domain,
class 5, transcription factor, Nanog homeobox; SRY-2 box,
the stage-speciﬁc embryonic antigen-4 (SSEA4) [10, 13]. For
example, in one report 44% of hAECs expressed SSEA4,
5–15% of cells expressed Oct-3/4, and 5–15% expressed
Nanong and/or Sox-2 [10]. Consistent with the expression
of such early lineage markers, the diﬀerentiation repertoire
of hAECs has been conﬁrmed in vitro using various tech-
niques (phenotypic, mRNA expression, immunocytochem-
ical, and/or ultrastructural characteristics), demonstrating
that hAECs derived from term placental membranes can
be successfully diﬀerentiated into cardiomyocytic, myocytic,
osteocytic, adipocytic (mesodermal), pancreatic, hepatic,
lung (endodermal), neural, and astrocytic (neuroectoder-
mal) cells [13, 14]. With regard to the lung, hAECs express
thyroid transcription factor or Nkx 2.1 mRNA, one of
the earliest lineage markers of the developing lung that
is essential for branching lung morphogenesis and type II
alveolar cell formation [14].
However, while hAECs express many markers of early
stem cells, they are not omnipotent like embryonic stem
cells. Indeed, there are a number of key diﬀerences between
hAECs and embryonic stem cells that suggest that hAECS
may be more suitable for clinical application. For example,
unlike embryonic stem cells (ESCs) and human induced
pluripotent stem (IPS) cell lines [15, 16], hAECs do not
form teratomas when injected into the testes of mice with
severe combined immunodeﬁciency (SCID) [13, 17]a n d
they maintain a normal karyotype and cell cycle distribution
with telomere stability over prolonged in vitro passaging
[10]. These observations suggest that the more limited
pluripotency displayed by hAECs, compared with ESCs or
IPS cells, will pose less risks for in vivo tumour formation
after-transplantation than those other stem cells. Further-
more, hAECs express no, or very little, class IA and class II
human leukocyte antigens (HLAs) [13, 18]. In fact, likely
reﬂecting their functions during pregnancy, hAECs express
the immunosuppressive human leukocyte antigen G (HLA-
G) that confers a degree of immune privilege by suppressing
NK cells, inducing apoptosis of activated CD8+ T-cells and
inhibiting CD4+ T cell proliferation [18, 19]. Such ﬁndings
are consistent with promoting maternal tolerance of a fetal
allograft (including its membranes) for the nine months of
human pregnancy. Such a property might also suggest a low
risk of tissue rejection when given therapeutically. So far this
indeed appears true. Following xenotransplantation hAECs
can survive for prolonged periods in immune competent
monkeys, rabbits, guinea pigs, rats, and swine without
immunorejection, albeit without conﬁrmed in vivo diﬀer-
entiation [19–22]. In one study hAECs transplanted into
neonatal swine and rats resulted in human microchimerism
in various organs and tissues without immune clearance
[19]. Furthermore, hAECs injected into healthy human
volunteers did not elicit any clinical signs of acute rejection
and recipients did not produce antibodies against HLA
antigens [23]. However, while undiﬀerentiated hAECs do
not express HLAs, apart from HLA-G, it would appear
that as they are made to diﬀerentiate, at least in vitro, this
immune privileged state may be lost. For example, recently
we showed that, following diﬀerentiation into hepatic and
pancreatic lineages, signiﬁcant numbers of hAECs began to
express Class IA, but not Class II HLA [13]. The clinical
signiﬁcance of this ﬁnding for future cell transplantation
remains unclear but suggests that cells diﬀerentiated in vitro
prior to transplantation may be less suitable for allogeneic
use than primary undiﬀerentiated cells. We will revisit this
theme later.
3. Endogenous LungStem Cells
Before any discussion of stem-cell-mediated lung repair, it
is useful to distinguish the roles and activities of exogenous
stemcells,suchashAECs,fromthoseofresidentendogenous
lung stem cells. While the very slow natural turnover
of lung and bronchial epithelia and the multiple distinct
anatomical zones of the lung have made the identiﬁcation
of lung stem cells diﬃcult [24–26], a number of diﬀerent
resident lung stem or progenitor cells have been identiﬁedStem Cells International 3
[27, 28]. It is thought that each of these progenitor cell
niches provides speciﬁc repair mechanisms for the diﬀerent
parts of the respiratory tract and that diﬀerent injuries may
triggerdiﬀerential responses from the various progenitor cell
populations[25,27,28].Speciﬁcally,distinctprogenitorcells
have been identiﬁed in the proximal trachea, the bronchi,
the bronchioli, the bronchiolar-alveolar junction, and the
alveoli [24, 25, 28]. Of these various lung progenitor/stem
cells, specialized nonciliated airway epithelial cells called
Clara cells, or variant Clara cells, respond to airway injury
by replenishing the ciliated epithelium, particularly in the
bronchioli and at bronchiolar-alveolar junction, while alve-
olar type II (ATII) cells are thought to be the principle
repair mechanism in the alveoli [25, 26, 28]. With regard
to exogenous stem cells and lung repair, the endogenous
“resident” lung progenitor/stem cells are likely to be impor-
tant. As will be discussed later, while it was initially thought
that exogenous stem cells aﬀected lung repair by integrating
into the damaged epithelium and diﬀerentiating into lung
cells, it is more likely that the principal mechanism whereby
they eﬀect repair is via immunomodulation [29]a n db y
supporting endogenous lung stem cell activity. Indeed, while
the lung contains its own population of resident endogenous
stem cells, it is thought that their regenerative eﬀorts become
exhausted during severe injury, leading to both acute and
chronic respiratory embarrassment. It is this feature that
makes the lung a particularly receptive organ for exogenous
cell therapy.
4 .A m nio nandM od el so fL ungI nj ury
The ﬁrst report of using amnion cells for repairing lung
injury was by Carraro and his colleagues [30]w h ou s e d
amnioticﬂuidstemcells(hAFSCs)obtainedfromamniocen-
tesis in midpregnancy. They assessed this mixed population
of cells that included hAECs, other epithelial cells, and
mesenchymal cells with regard to their reparative abilities
in two diﬀerent murine models of lung injury. First,
they demonstrated that hAFSCs could engraft into mouse
embryonic lung explants in vitro and diﬀerentiate into a
lung-type cell, as evidenced by the expression of thyroid
transcription factor 1 (TTF1). Then, to assess the ability of
hAFSCs to repair alveolar lung injury they administered the
cells to mice following short-term hyperoxia. The hAFSCs
migrated to the distal lung and expressed both TTF1 and
the type II alveolar cell product surfactant protein C. Next,
hAFSCs were administered to mice which had undergone
naphthalene lung injury. Naphthalene targets Clara cells in
the airways. As with the hyperoxia alveolar injury model,
the hAFSCs traﬃcked to the sites of injury—this time in a
bronchoalveolar junction and bronchial distribution rather
than the alveoli—and expressed the Clara cell 10kDa pro-
tein. This ﬁrst report highlighted two key properties of cells
derived from amniotic ﬂuid: their ability to track to speciﬁc
sites of injury and their plasticity to respond speciﬁcally to
the nature of the lung insult itself, diﬀerentiating into the
cell type that had been injured. Importantly, while the origin
of these cells was from a mixed population isolated from
amniotic ﬂuid, the cells had been sorted by c-kit positivity—
a stem cell marker—and derived from clonal cultures to
further select for stem cell-like behaviour. Therefore, it was
notsurprisingthatthecellsdisplayedpluripotency.However,
in neither of the two injury models was there evidence
of amelioration of injury. This suggests that integration
and diﬀerentiation in vivo are not suﬃcient for exogenous
stem cells to eﬀect repair. Furthermore, translating this cell
therapy into clinical practice may have some limitations.
The cells were derived from amniotic ﬂuid by amniocentesis,
selected by c-kit expression and then expanded and puriﬁed
through clonal isolation. Such a source is not likely to be
ar e a d ys o u r c eo fs u ﬃcient cells for widespread application
because amniocentesis is an invasive procedure that carries a
riskofmiscarriage.Itisunlikelythatwomenwillbeprepared
to expose their pregnancy to such risks for the beneﬁts of
others. It is also unlikely that suﬃcient numbers of cells will
be able to be derived for widespread application, although
expansion would be feasible.
Utilising placentae from term births is one strategy
to circumvent these problems entirely. Cargnoni and her
coworkers [31] transplanted a mixed population of fetal
membrane-derived cells from the amnion and chorion from
both allogeneic and xenogeneic (50% human mesenchymal
cells, 50% hAECs) sources, to a murine bleomycin model
of adult idiopathic pulmonary ﬁbrosis (IPF). Importantly,
unlike the amniotic ﬂuid derived cells used by Carraro and
colleagues, the cells used by Cargnoni were primary cells
that had not been selected for either c-kit expression or
clonal activity. Bleomycin produces many of the histological
hallmarks of IPF such as intra-alveolar buds, mural incor-
poration of collagen, and obliteration of the alveolar space
[32]. Both allogeneic and xenogeneic populations of mixed
primary cells, administered either systemically or intraperi-
toneally, mitigated lung ﬁbrosis to a similar extent and
markedly reduced neutrophil inﬁltration, a key prognostic
determinant of IPF. Persistence of both cell populations was
detected in the lung 14 days after administration conﬁrming
engraftment, albeit without conﬁrmed diﬀerentiation into
a lung phenotype. Indeed, it is unclear if engraftment is
even essential for their therapeutic eﬀect. The same group
had earlier demonstrated microchimerism in the lung at 90
days only by PCR after intraperitoneal injection of a similar
xenogeneic population of cells. That ﬁnding suggests that the
signiﬁcance of the engraftment seen in the second study was
likely to be modest [19, 31].
Extending these early reports, Moodley and colleagues
[14] also used the bleomycin model of lung injury in
SCID mice with the aim of examining diﬀerentiation of
the cells into lung phenotypes in more detail. In this study
a pure population of primary, unselected hAECs derived
from term placental membranes were used. First, primary
undiﬀerentiatedhAECswereculturedinsmallairwaygrowth
media(SAGM),knowntoinducediﬀerentiationofumbilical
mesenchymal cells and embryonic stem cells into type II
pneumocytes [33, 34], to explore whether hAECs could
be directed down an alveolar epithelial phenotype lineage.
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partially diﬀerentiate into lung cells, producing surfactant
proteins A, B, C, D and displaying ultrastructural evidence
of lamellar bodies, an organelle of type II pneumocytes.
Further, these cells responded to a glucocorticoid trigger and
were capable of secreting surfactant D [14]. None of these
features were present in freshly isolated hAECs. Primary,
undiﬀerentiated hAECs (lacking surfactant proteins) were
also injected intravenously into bleomycin treated SCID
mice and were shown to engraft and produce all surfactant
proteins [14]. This suggested an ability of primary hAECs
to diﬀerentiate into lung cells in vivo—similar to the
observations made by Carraro of selected and puriﬁed
amniotic derived cells [30]. However, unlike the amni-
otic ﬂuid derived cells, hAEC administration signiﬁcantly
reduced bleomycin-induced lung ﬁbrosis and inﬂamma-
tion [14]. Speciﬁcally, levels of pro-inﬂammatory cytokines
were reduced (monocyte chemo-attractant protein-1, tumor
necrosis factor-alpha, IL-1 and IL-6) and anti-inﬂammatory
cytokines were increased (IL-10 and macrophage migration
inhibitory factor). Expression of the proﬁbrotic cytokine
transforming growth factor-beta was also reduced by hAECs
administration. In keeping with these cytokine changes,
lung collagen content was reduced, reported to be a con-
sequence of increased action of matrix metalloproteinase-
2 and down-regulation of the tissue inhibitors of matrix
metalloproteinase-1 and 2 consistent with lung repair.
hAECs also seemed to reduce established ﬁbrosis in one
small group of mice, with a reduced collagen content
conﬁrmed with the delayed administration of hAECs two
weeks after the bleomycin insult. This comprehensive study
demonstrated that a pure population of primary hAECs
d e r i v e df r o mt e r mp l a c e n t aa f t e rc o m p l e t i o no fap r e g n a n c y
had the ability to prevent and repair acute lung injury
induced by bleomycin. The authors suggested that the cells
exerted these aﬀects via modulation of the host response to
injury and by in vivo diﬀerentiation [14].
However, while subsequent studies have conﬁrmed the
injury prevention abilities of hAECs, they have cast some
doubt on the mechanisms by which hAECs eﬀect this.
Using the bleomycin model of lung injury, Murphy et al.
[29] advanced the ﬁeld by the administration of a pure
population of undiﬀerentiated hAECs to immune compe-
tent, as opposed to immune compromised, mice. In this
study, intraperitoneal administration of hAECs 24hrs after
bleomycin administration decreased lung ﬁbrosis, evidenced
by reduced collagen deposition and alpha-smooth muscle
actin, and decreased lung inﬂammation and the expression
of proinﬂammatory cytokines [29]. Moving one step further,
this was to the ﬁrst study to demonstrate that the miti-
gation of structural lung injury by hAECs was associated
with a partial restoration of physiological lung function,
as assessed by whole body plethysmography. However, in
contrast to the previous studies—all performed in immune
compromisedmice—Murphyandhiscolleagueswereunable
to demonstrate any engraftment of hAECs in the lung [29].
Based on this observation, some doubt was cast on the likely
mechanism(s) by which hAECs may work.
5. MechanismsofActionofhAECs:Engraftment
versus Immunomodulation
It is fair to say that, at present, there remains some uncer-
tainty about the primary mechanism(s) by which hAECs
aﬀect lung injury prevention/repair. Speciﬁcally, whether
in vivo engraftment and diﬀerentiation are necessary or
whether modulation of the host response to injury that
then reduces inﬂammation and ﬁbrosis, either directly or
indirectly,iskey.Atthisstageitwouldappearthatthelatteris
the more likely. Our recent report [29] clearly demonstrated
that hAECs can exert a reparative eﬀect without the need for
engraftment or diﬀerentiation and the work of Carraro and
his colleagues showed that engraftment and diﬀerentiation
per se was not suﬃcient for injury prevention/repair [30].
The apparent inconsistencies between studies regarding
whether in vivo integration and diﬀerentiation of hAECS
following injury actually occurs may be explained by the
methods used to identify hAECs in vivo. Murphy et al. [29]
chose ﬂuorescence-activated cell sorting (FACS) with gating
applied to exclude dead cells to detect only live resident
human cells. Previous studies relied on PCR or in situ
hybridization for human DNA or immunohistochemistry.
These latter methods are all unable to discern living from
dead cells [14, 30, 31] and so it is possible that those
studies were simply reporting dead cells. Of course, this does
not explain the in vivo identiﬁcation of surfactant protein-
expressing hAECs [14]. Nonetheless, we have suggested that
the primary mechanism of injury repair in their study was
likely to be paracrine signaling to the surrounding tissues
to reduce proinﬂammatory and proﬁbrotic mediators [29].
This is consistent with previous reports of a beneﬁcial
eﬀect of amnion where cellular diﬀerentiation has not
been conﬁrmed, such as in brain ischaemia, Parkinson’s
disease, spinal cord injury, myocardial ischaemia, critical
limb ischemia, burns and skin wounds [20, 35–39].
The exact identity of antiinﬂammatory and anti-ﬁbrotic
factors that might be released by amnion cells remains to
be elucidated. However, the ophthalmology literature has
described for some time the beneﬁcial eﬀect of amnion for
corneal ulcers mediated through a reduction in HLA Class
II antigen presenting cells at the site of injury, reduction
in apoptosis and inﬂammation [40]. This literature suggests
hAECs are able to inhibit the chemotactic migration of
neutrophils and macrophages to the site of injury, possibly
via MIF and suppression of IL-1α,I L - 1 β, and proteinase
[41], similar to that shown by Moodley et al. [14]. Indeed,
hAEC-induced suppression of macrophage and neutrophil
migration into the injured lung has been a consistent ﬁnding
[29, 31]. This is supported by the observation that hAECs
decrease macrophage migration in vitro [42]. That hAECs
modulate macrophage and/or neutrophil migration is likely
to be important in the context of lung injury because both
macrophages [43] and neutrophils [44] play important roles
in mediating such injury. In this regard, very recently we
showed that hAECs were unable to mitigate bleomycin-
inducedlunginjuryinSP-Cknock-outmice[42].Thisstrain
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with macrophages unable to switch from an M1 (pro-
ﬁ b r o t i c )p h e n o t y p et oa nM 2( r e p a r a t i v e )p h e n o t y p e .W e
suggested that this observation was consistent with hAECs
exerting their reparative eﬀects via macrophages rather than
directly [42].
Of course, hAECs may operate through other mech-
anisms too. For example, they express the anti-inﬂamma-
tory IL-1 receptor antagonist, IL-10, collagen XVIII, throm-
bospondin-1 and all four tissue inhibitors of metallopro-
teinase (TIMPs) [45]. Apoptosis of leucocytes has been
reported and hAECs express apoptosis-inducing genes Fas
L, TNF, and TRAIL [41, 46]. Furthermore, there is evidence
to support an anti-angiogenenic eﬀect through release of
endostatin, TSP-1 and TIMPs and the antibacterial protein
lactoferrin [47]. The relative contributions of these pathways
to amnion cell-mediated tissue repair will clearly require a
considerable amount of working through.
In relation to ﬁbrosis, human corneal and limbal ﬁbrob-
lasts grown on the matrix surface of amniotic membranes
displayed marked down regulation of TGFβ-signalling sys-
tem with decreased expression of TGFβ-1, β-2 and β-3 iso-
formsandreducedexpressionofTGF-ReceptorIIpreventing
ﬁbroblast activation into myoﬁbroblasts [48]. Furthermore,
amniotic membrane is also capable of reversing already
diﬀerentiated myoﬁbroblasts back into a ﬁbroblast pheno-
type, which may be particularly useful for ameliorating
more established disease [49]. Since TGF-β signalling plays a
centralroleinpulmonaryﬁbrosis[50]theabilityofhAECsto
decrease TGF-β signalling and prevent ﬁbroblast activation
is likely to be an important eﬀector mechanism in their
reparative properties.
6.Towards ClinicalTrials
Before hAECs can be eﬀectively translated into a future
cellular therapy for lung injury a number of questions need
resolving. It would be useful if the identity of the anti-
inﬂammatory and antiﬁbrotic signaling pathways at play are
characterized. It may be possible that these pathways can
be manipulated pharmacologically rather than necessitate
cell delivery. In this way, the reparative abilities of hAECs
would have been used to develop new drug-based therapies
by revealing the key pathways that need targeting. However,
such an endeavour will be considerable and more immediate
therapy may be aﬀorded by simply administering cells. If
this is the case then it will also be necessary to deter-
mine the optimum cell type for transplantation, whether
that be undiﬀerentiated hAECs, or hAEC-derived partially
diﬀerentiated lung progenitor cells, or even a mixed cell
population. As detailed earlier, the hAECs used in the studies
todatehavebeenunselected,primarycells—aheterogeneous
population of epithelial cells. It is possible that only a subset
of these cells are reparative and that by identifying and
purifying those cells more eﬀective regenerative therapies
can be developed. Of course, it is also possible that it
is the heterogeneous nature of the population that is a
key attribute of the therapy, providing diverse cells to
undertake diverse roles at diﬀerent stages of tissue injury-
repair-resolution. If this is so then puriﬁed subpopulations
of cells may prove to be less, rather than more, eﬀective. It
is also unknown whether both undiﬀerentiated and partially
diﬀerentiated cells equally eﬀect immunomodulation. This
wouldbeimportanttodeﬁnebeforeembarkinguponclinical
trials. From a pragmatic perspective, regulatory authorities
aremorelikelytoapproveprimary,unmanipulatedcellsthan
cells that have undergone extensive puriﬁcation, selection,
and diﬀerentiation. However, if diﬀerentiated cells are more
eﬀective then these should form the basis of future therapies.
With regard to regulatory approval and cell handling,
it will also be necessary for future studies to adhere to
good manufacturing practice (GMP) processes suitable for
clinical use, as has already been described [10, 51], to readily
ensure standardization and clinical applicability moving
forward. Should hAECs prove useful clinically, such stand-
ardization will be a foundation of cell banks. We believe
that while autologous use of hAECs may oﬀer a safe ﬁrst
step application, for example in preterm neonates with
bronchopulomonary dysplasia [26], ultimately widespread
use of hAECs will require the development of biobanks of
high quality cells for allogeneic application, most likely in an
alpha clinic setting [52]. The clinics and cell banks will be
necessarysimplybecausethemajorityofpatientsdonothave
their own amnion cells in storage.
Finally, and possibly most importantly, all of the studies
performed to date have administered hAECs very early
during the injurious process in the lung. There has been
no comprehensive assessment of whether hAECs are able
to repair established and long-standing lung injury. This is
clearly critical because the most common clinical application
of cell therapy for lung disease will be to those individuals
with chronic, established and extensive lung injury. This is
where the current clinical burden lies and where current
therapies desperately fail.
7. Conclusion
There is no question that acute and chronic lung disease
require novel therapies. Preclinical studies have shown that
amnion cells are able to reduce ﬁbrosis and inﬂamma-
tion, and thereby improve lung function. However, several
questions remain unanswered, including whether how these
cells work, whether there are subpopulations of cells that
are most eﬀective, and whether amnion cells are able to
repair established disease. We are indeed hopeful that the
immunomodulatory concert that is present at the maternal-
fetal interface during pregnancy may soon extend long after
birth to oﬀer new therapies for suﬀerers of chronic lung
disease.
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